Everything below concerns peptide stability. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
=== The supraoptic nucleus as a "model system" === The supraoptic nucleus is an important "model system" in neuroscience. There are many reasons for this: Some technical advantages of working on the supraoptic nucleus are that the cell bodies are relatively large, the cells make exceptionally large amounts of their secretory products, and the nucleus is relatively homogeneous and easy to separate from other brain regions. The gene expression and electrical activity of supraoptic neurons has been studied extensively, in many physiological and experimental conditions.
The driver, Nicolaas Fourie, and his two passengers promptly surrendered and were disarmed. After the media were allowed to photograph the badly injured prisoners, they were then executed at point-blank range by a Bophuthatswana policeman, Ontlametse Bernstein Menyatswe. These killings effectively spelt the end of white right-wing military opposition to democratic reforms. On 12 March 1994, Mangope was deposed as President of Bophuthatswana by the South African government and the Transitional Executive Council. South African Ambassador to Bophuthatswana, Prof. Tjaart van der Walt, was then appointed as the territory's new administrator.
== Concerns == Concerns over AI agents include potential issues of liability, an increased risk of cybercrime, ethical challenges, and problems related to AI safety and AI alignment. Other issues involve data privacy, weakened human oversight, a lack of guaranteed repeatability, reward hacking, algorithmic bias, compounding software errors, lack of explainability of agents' decisions, security vulnerabilities, stifling competition, problems with underemployment, job displacement, cognitive offloading, and the potential for user manipulation, misinformation or malinformation. They may also complicate legal and risk-assessment frameworks, foster hallucinations, hinder countermeasures against rogue agents, and suffer from the lack of standardized evaluation methods. Enterprise deployment of AI agents has raised contracting concerns related to liability allocation, data ownership rights, and legal accountability. They have also been criticized for being expensive, having a negative impact on internet traffic, and potentially damaging to the environment due to high energy usage. According to Nvidia CEO Jensen Huang, AI agents would require 100 times more computing power than LLMs. There is also the risk of increased political corruption, as AI agents may not question instructions in the same way that humans would. Journalists have described AI agents as part of a push by Big Tech companies to "automate everything". Several of those companies' CEOs stated in early 2025 that they expect AI agents to eventually "join the workforce".
These non-peptide inhibitors can be more stable than inhibitors containing peptide bonds, because they will not be substrates for peptidases and are less likely to be degraded. In drug design it is important to consider the concentrations of substrates to which the target enzymes are exposed. For example, some protein kinase inhibitors have chemical structures that are similar to ATP, one of the substrates of these enzymes. However, drugs that are simple competitive inhibitors will have to compete with the high concentrations of ATP in the cell. Protein kinases can also be inhibited by competition at the binding sites where the kinases interact with their substrate proteins, and most proteins are present inside cells at concentrations much lower than the concentration of ATP. As a consequence, if two protein kinase inhibitors both bind in the active site with similar affinity, but only one has to compete with ATP, then the competitive inhibitor at the protein-binding site will inhibit the enzyme more effectively.
Sources: en.wikipedia.org
=== 4 March === Ukrainian forces reportedly began their withdrawal from Bakhmut and reports stated that many civilians fled from the city. Rheinmetall, a German military vehicle and weapons manufacturing company, is reported to be negotiating with the government of Ukraine about the possibility of building a tank factory in Ukraine. The proposed factory would cost about 200 million euros and be capable of producing up to 400 Panther KF51 tanks per year. Armin Papperger, the CEO, reportedly argues that Ukraine would need about 600 to 800 new tanks to win the war, which is more than the 300 existing tanks that Germany could supply them with. The Ukrainian Defence Minister, Oleksiy Reznikov, wrote a letter to the European Union asking for 250,000 155mm shells per month. Ukrainian forces use approximately 110,000 155mm shells per month. He claimed that Ukrainian forces were only firing a fifth of what they could due to shortages. The Ukrainian hope is to use "594,000" shells per month. NATO is considering establishing factories in Eastern Europe to increase production of Soviet era ammunition.
Poultices are used on horses to relieve inflammation. Usually applied to the lower legs, under a stable bandage, to focus treatment on the easily injured tendons in the area. Poultices are sometimes applied as a precautionary measure after the horse has worked hard, such as after racing, jumping, or cross-country riding, to forestall strains or stiffness. They may be used to treat abscesses, with the intention of drawing out pus from the wound. Cooling poultices are sometimes used for show-jumpers and racehorses; these may be cheaper and easier to administer than commercial cooling products. A poultice is applied to the horse's distal limbs after exercise, for 9–12 hours. The intended effect is to cool the legs over a long period of time, by dispersing heat from the limb through the action of evaporation. Commonly, the poultice is bandaged over, sometimes with materials such wet newspaper between the poultice and bandages; this greatly reduces evaporation and heat loss, rendering the poultice ineffective at cooling.
William said in 1985, "We all love The Shangri-Las, and one day we're going to make Shangri-Las records." Jim mentioned his liking for Pink Floyd, Siouxsie and the Banshees, The Monkees, and Muddy Waters. Early demos displayed a similarity to the Ramones, prompting the brothers to add another element to their sound; in William's words: "That's why we started using noise and feedback. We want to make records that sound different." They began playing live in early 1984. In the early days William Reid's guitar would be left out of tune, while Dalglish's drum kit was limited to two drums, and Hart's bass guitar only had three strings, down to two by 1985; in Hart's words, "That's the two I use. I mean what's the fucking point spending money on another two? Two is enough." Struggling to get gigs, the band took to turning up at venues claiming to be the support band, playing their short set and making a quick exit. After failing to generate any interest from concert promoters and record labels in Scotland, the band relocated to Fulham, London, in May 1984, and soon afterwards their demo tape was passed to fellow Scot Alan McGee by Bobby Gillespie. Subsequently, McGee promoted a gig for the band at the Living Room in London in June 1984. On the strength of hearing the band sound check, McGee signed them to his Creation Records label on a one-off deal, and McGee also became the band's manager. Their debut single, "Upside Down", was recorded in October and released in November that year.
==== South Korea ==== Dubu plays an important part in Korean cuisine. Tofu is often pan-fried and served as banchan with a dipping sauce. It is also used in many soups. Cubes of firm tofu can be seasoned with soy sauce, garlic, and other ingredients before pan-frying. A dish of tofu cubes simmered with similar spicy seasoning is called dubu-jorim. Dubu-kimchi features blanched tofu served in rectangular slices around the edges of a plate with pan-fried kimchi. This is a popular food to accompany alcoholic drinks (anju). Soft, unpressed sun-dubu is used as the main ingredient of sundubu-jjigae (soft tofu stew), while other soups and stews such as doenjang-guk (soybean paste soup), doenjang-jjigae (soybean paste stew), and kimchi-jjigae (kimchi stew) tend to have diced firm tofu in them. As in many other East Asian countries, tofu is also enjoyed in a hot pot dish called dubu-jeongol (tofu hot pot).
A theoretical plate in many separation processes is a hypothetical zone or stage in which two phases, such as the liquid and vapor phases of a substance, establish an equilibrium with each other. Such equilibrium stages may also be referred to as an equilibrium stage, ideal stage, or a theoretical tray. The performance of many separation processes depends on having series of equilibrium stages and is enhanced by providing more such stages. In other words, having more theoretical plates increases the efficiency of the separation process be it either a distillation, absorption, chromatographic, adsorption or similar process.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.